Hong Kong, China — Recently, the AnchorMan^® Left Atrial Appendage Closure System (AnchorMan^® LAAC system), independently developed by Shanghai MicroPort CardioAdvent Co., Ltd, a wholly-owned subsidiary of MicroPort CardioFlow Medtech Corporation (CardioFlow, 02160.HK), achieved its first clinical application in Hong Kong at Canossa Hospital – Hong Kong Asia Heart Centre. The procedure successfully implemented a stroke prevention solution for an elderly patient at high risk of stroke. Post-operation, the closure remained stable with no complications, marking a significant breakthrough in the strategic deployment of this innovative product in the Chinese market.

The procedure was completed by a team led by two specialists from Hong Kong Asian Heart Centre: Professor Yixian Lin, Director of Cardiology Department, and Dr. Manho Wong. As a leading authority in cardiovascular care in Hong Kong, the centre provided critical support for the successful completion of the procedure, leveraging its top-tier expert team and advanced technical capabilities.

The patient was an 86-year-old female with paroxysmal atrial fibrillation (AF). Due to kidney disease, she could not take oral anticoagulants. Her CHA2DS2-VASc score was 4, and her HAS-BLED score was 3, indicating high stroke and bleeding risks. Preoperative transesophageal echocardiography (TEE) confirmed no thrombus in the left atrium or left atrial appendage (LAA).

The LAA had a bilobed, cauliflower-shaped morphology, with an ostium diameter of approximately 21.81 mm and a depth of 25.38 mm. A 29 mm AnchorMan^® LAAC system was selected for the procedure. During the operation, the delivery sheath was rotated counterclockwise to access the superior lobe, and the closure was deployed using a combination of the "unsheathing method" and "push-pull technique." The case results showed optimal positioning of the closure in the LAA with stable anchoring confirmed via tug test. The compression ratio ranged between 17.2% and 20.7%, with no residual flow or other complications observed.

The surgical team highly praised the clinical performance of the AnchorMan^® LAAC system and expressed interest in further collaboration. Professor Yixian Lin remarked post-procedure:

"The closure expanded evenly outward, achieving complete sealing of the LAA ostium. Moreover, during the tug test, the device remained firmly in place without displacement, demonstrating excellent stability."

Since its launch in China in early 2024, the AnchorMan^® LAAC system has shown strong momentum, achieving a milestone of 500 implants within just one year. Its business footprint has rapidly expanded from mainland China to Macau, and now to Hong Kong, where this successful procedure marks a continued deepening of its strategic presence in the Chinese market. Previously, the device also completed its first post-EU-certification implant in Poland, highlighting significant progress in its globalization strategy. As the product continues to expand in domestic and international markets, this innovative treatment is expected to provide superior therapeutic options for more AF patients worldwide.